Efficacy and tolerability of treatments for bipolar depression

Journal of Affective Disorders

Volumn 183, Issue , 2015, Pages 258-262

  Vázquez, Gustavo H ^a,b   Holtzman, Jessica N ^b,c   Tondo, Leonardo ^a,d,e   Baldessarini, Ross J ^a,d  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF PALERMO   (Argentina)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Lucio Bini Mood Disorders Center   (Italy)

Author keywords

Bipolar depression; Number needed to harm (NNH); Number needed to treat (NNT); Treatments

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; LAMOTRIGINE; LITHIUM; LURASIDONE; OLANZAPINE; QUETIAPINE; VALPROIC ACID; ZIPRASIDONE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; DRUG COMBINATION; FLUOXETINE PLUS OLANZAPINE; NEUROLEPTIC AGENT;

AKATHISIA; ARTICLE; BIPOLAR DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; METABOLIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEDATION; WEIGHT GAIN; BIPOLAR DISORDER; DRUG COMBINATION;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; LURASIDONE HYDROCHLORIDE; QUETIAPINE FUMARATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84930198585     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2015.05.016     Document Type: Article

References (40)

1. V. Agosti, and J.W. Steward Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression Int. Clin. Psychopharmacol. 22 2007 309 311
2. R.J. Baldessarini Chemotherapy in Psychiatry 2013 Springer Press New York
3. R.J. Baldessarini, H. Henk, A. Sklar, J. Chang, and L. Leahy Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence Psychiatr. Serv. 59 2008 1175 1183
4. D.J. Bond, R.W. Lam, and L.N. Yatham Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis J. Affect. Disord. 124 2010 228 234
5. E.B. Brown, S.L. McElroy, P.E. Keck Jr., A. Deldar, D.H. Adams, M. Tohen, and D.J. Williamson Seven-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression J. Clin. Psychiatry 67 2006 1025 1033
6. J.R. Calabrese, C.L. Bowden, G.S. Sachs, J.A. Ascher, E. Monaghan, and G.D. Rudd A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression J. Clin. Psychiatry 60 1999 79 88
7. J.R. Calabrese, P.E. Keck, W. Macfadden, M. Minkwitz, T.A. Ketter, R.H. Weisler, A.J. Cutler, R. McCoy, E. Wilson, and J. Mullen A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am. J. Psychiatry 162 2005 1351 1360
8. L. Citrome, T. Ketter, J. Cucchiaro, and A. Loebel Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed J. Affect. Disord. 155 2014 20 27
9. J.B. Cohn, G. Collins, E. Ashbrook, and J.F. Wernicke A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder Int. Clin. Psychopharmacol. 4 1989 313 322
10. J. Cookson, P.E. Keck Jr., T.A. Ketter, and W. Macfadden Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study Int. Clin. Psychopharmacol. 22 2007 93 100
11. L.L. Davis, A. Bartolucci, and F. Petty Divalproex in the treatment of bipolar depression: placebo-controlled study J. Affect. Disord. 85 2005 259 266
12. A.J. Ferrari, F.J. Charlson, R.E. Norman, S.B. Patten, G. Freedman, C.J.L. Murray, T. Vos, and H.A. Whiteford Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010 PLoS Med. 10 2013 e1001547
13. A. Forte., R.J. Baldessarini, L. Tondo, G.H. Vázquez, M. Pompili, and P. Girardi Long term morbidity in bipolar I, bipolar II, and unipolar major depressive disorders J. Affect. Disord. 2015
14. S.N. Ghaemi, W.S. Gilmer, J.F. Goldberg, B. Zablotsky, D.E. Kemp, M.E. Kelley, A.D. Bauer, J. Fleck, M.M. Filkowski, V.A. Stan, and R.T. Dunn Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study J. Clin. Psychiatry 68 2007 1840 1844
15. S.N. Ghaemi, A.F. Wingo, M.A. Filkowski, and R.J. Baldessarini Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks Acta Psychiatr. Scand. 118 2008 347 356
16. A. Loebel, J. Cucchiaro, R. Silva, H. Kroger, J. Hsu, K. Sarma, and G.S. Sachs Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am. J. Psychiatry 171 2014 160 168
17. A. Loebel, J. Cucchiaro, R. Silva, H. Kroger, K. Sarma, J. Xu, and J.R. Calabrese Lurasidone as adjunctive therapy with Lithium or Valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am. J. Psychiatry 171 2014 169 177
18. I. Lombardo, G. Sachs, S. Kolluri, C. Kremer, and R. Yang Two 6-week, randomized, double-blind, placebo-controlled studies of Ziprasidone in outpatients with bipolar I depression J. Clin. Psychopharmacol. 32 2012 470 478
19. A. Martinez-Arán, E. Vieta, F. Colom, C. Torrent, J. Sánchez-Moreno, M. Reinares, A. Benabarre, J.M. Goikolea, E. Brugué, C. Daban, and M. Salamero Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome Bipolar Disord. 6 2004 224 232
20. S.L. McElroy, R.H. Weisler, W. Chang, B. Olausson, B. Paulsson, M. Brecher, V. Agambaram, C. Merideth, A. Nordenhem, and A.H. Young Double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II) J. Clin. Psychiatry 71 2010 163 174
21. D.J. Muzina, K. Gao, D.E. Kemp, S. Khalife, S.J. Ganocy, P.K. Chan, M.B. Serrano, C.M. Conroy, and J.R. Calabrese Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: double-blind, randomized, placebo-controlled trial J. Clin. Psychiatry 72 2011 813 819
22. C.B. Nemeroff, D.L. Evans, L. Gyulai, G.S. Sachs, C.L. Bowden, I.P. Gergel, R. Oakes, and C.D. Pitts Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression Am. J. Psychiatry 158 2001 906 912
23. I. Pacchiarotti, D.J. Bond, R.J. Baldessarini, W.A. Nolen, H. Grunze, R.W. Licht, R.M. Post, M. Berk, G.M. Goodwin, G.S. Sachs, L. Tondo, R.L. Findling, E.A. Youngstrom, M. Tohen, J. Undurraga, A. González-Pinto, J.F. Goldberg, A. Yildiz, L.L. Altshuler, J.R. Calabrese, P.B. Mitchell, M.E. Thase, A. Koukopoulos, F. Colom, M. Frye, G.S. Malhi, K.N. Fountoulakiss, G.H. Vázquez, R.H. Perlis, T.A. Ketter, F. Cassidy, H. Akiskal, J.M. Azorin, M. Valentí, D.H. Mazzei, B. Lafer, T. Kato, L. Mazzarini, A. Martínez-Aran, G. Parker, D. Souery, A. Özerdem, S.L. McElroy, P. Girardi, M. Bauer, Y.N. Yatham, C.A. Zarate Jr., A.A. Nierenberg, B. Birmaher, S. Kanba, R.S. El-Mallakh, A. Serretti, Z. Rihmer, A.H. Young, G.D. Kotzalidis, G.M. MacQueen, C.L. Bowden, S.N. Ghaemi, C. Lopez-Jaramillo, J. Rybakowski, K. Ha, G. Perugi, S. Kasper, J.D. Amsterdam, R.M. Hirschfeld, F. Kapczinski, and E. Vieta International Society for Bipolar Disorders (ISBD) task-force report on antidepressant use in bipolar disorders Am. J. Psychiatry 170 2013 1249 1262
24. J.G. Reid, M.J. Gitlin, and L.L. Altshuler Lamotrigine in psychiatric disorders J. Clin. Psychiatry 74 2013 675 684
25. G.S. Sachs, A.A. Nirenber, J.R. Calabrese, L.B. Marangell, S.R. Wisniewski, L. Gyulai, E.S. Friedman, C.L. Bowden, M.D. Fossey, M.J. Ostacher, T.A. Ketter, J. Patel, P. Hauser, D. Rapport, J.M. Martinez, M.H. Allen, D.J. Miklowitz, M.W. Otto, E.B. Dennehy, and M.E. Thase Effectiveness of adjunctive antidepressant treatment for bipolar depression N. Engl. J. Med. 356 2007 1711 1722
26. K.E.A. Sanders, and G. Goodwin Course of bipolar disorder Adv. Psychiatr. Treat. 16 2010 318 328
27. V. Selle, S. Schalkwijk, G.H. Vázquez, and R.J. Baldessarini Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium, and second-generation antipsychotics Pharmacopsychiatry 47 2014 43 52
28. T. Suppes, C. Datto, M. Minkwitz, A. Nordenhem, C. Walker, and D. Darko Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression J. Affect. Disord. 121 2010 106 115
29. M.E. Thase, W. Macfadden, R.H. Weisler, W. Chang, B. Paulsson, A. Khan, and J.R. Calabrese Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study) J. Clin. Psychopharmacol. 26 2006 600 609
30. M.E. Thase, A. Jonas, A. Khan, C.L. Bowden, X. Wu, R.D. McQuade, W.H. Carson, R.N. Marcus, and R. Owen Aripiprazole monotherapy in non-psychotic bipolar I depression J. Clin. Psychopharmacol. 28 2008 13 20
31. M. Tohen, D.P. McDonnell, M. Case, S. Kanba, K. Ha, Y.R. Fang, H. Katagiri, and J.C. Gomez Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression Br. J. Psychiatry 201 2012 376 382
32. M. Tohen, E. Vieta, J. Calabrese, T.A. Ketter, G. Sachs, C. Bowden, P.B. Mitchell, F. Centorrino, R. Risser, R.W. Baker, A.R. Evans, K. Beymer, S. Dube, G.D. Tollefson, and A. Breier Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression Arch. Gen. Psychiatry 60 2003 1079 1088
33. L. Tondo, R.J. Baldessarini, and G.H. Vázquez Options for pharmacological treatment of refractory bipolar depression Curr. Psychiatry Rep. 16 2013 431
34. L. Tondo, G.H. Vázquez, and R.J. Baldessarini Mania associated with antidepressant-treatment: comprehensive meta-analytic review Acta Psychiatr. Scand. 121 2010 404 414
35. G.H. Vázquez, L. Tondo, J. Undurraga, and R.J. Baldessarini Overview of antidepressant treatment of bipolar depression Int. J. Neuropsychopharmacol. 16 2013 1673 1685
36. World Health Organization (WHO), 2012. Global Burden of Disease: Depression. (http://www.who.int/healthinfo/statistics/en/) and (http://www.who.int/mediacentre/factsheets/fs369/en/) (accessed 15.01.15).
37. L.N. Yatham, S.H. Kennedy, S.V. Parikh, A. Schaffer, S. Beaulieu, M. Alda, C. O'Donovan, G. MacQueen, R.S. McIntyre, V. Sharma, A. Ravindran, L.T. Young, R. Milev, D.J. Bond, B.N. Frey, B.I. Goldstein, B. Lafer, B. Birmaher, K. Ha, W.A. Nolen, and M. Berk Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder Bipolar Disord. 15 2013 1 44
38. A.H. Young, S.L. McElroy, M. Bauer, N. Philips, W. Chang, B. Olausson, B. Paulsson, and M. Brecher Double-blind, placebo-controlled study (EMBOLDEN I) of quietapine and lithium monotherapy in adults in the acute phase of bipolar depression J. Clin. Psychiatry 71 2010 150 162
39. Z.J. Zhang, W.H. Kang, Q.R. Tan, Q. Li, C.G. Gao, F.G. Zhang, H.H. Wang, X.C. Ma, C. Chen, W. Wang, L. Guo, Y.H. Zhang, X.B. Yang, and G.D. Yang Adjunctive herbal medicine with carbamazepine for bipolar disorders: double-blind, randomized, placebo-controlled study J. Psychiatr. Res. 41 2007 3609
40. P. Zimmermann, T. Brückl, A. Nocon, H. Pfister, R. Lieb, H.U. Wittchen, F. Holsboer, and J. Angst Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity Arch. Gen. Psychiatry 66 2009 1341 1352